Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON

Toonaangevende leiders

Alle informatieOndernemingenMarktenEconomie & ForexgrondstoffenRenteToonaangevende leidersFinanciŽle professionalAgendaSectoren 
HomepaginaAl het nieuwsHet meest gelezen nieuwsBiografieŽn van de Leiders
Overzicht 
Dr. Graham K. Dixon is an Independent Director at Alligator Bioscience AB, a Chairman at HepaRegeniX GmbH, a CSO, Head-Research & Development at Mithra Pharmaceuticals SA and a Head-Research & Development at Zaluvida Holdings Pte Ltd.

He is on the Board of Directors at Alligator Bioscience AB and InteRNA Technologies BV. Dr. Dixon was previously employed as a CSO, Head-Research & Development by Onxeo SA, a CSO, Head-Research & Development by Addex Therapeutics Ltd., a Senior Vice President-Drug Discovery by Galapagos NV, a Chief Scientific Officer by F2G Ltd., a Head-Research & Development by AstraZeneca Plc, a Head-Research & Development by Zeneca, a Chief Scientific Officer by Entomed SA, a Chief Scientific Officer by Galapagos Genomics NV, a Chief Executive Officer by Neem Biotech Ltd., and a CSO, Head-Research & Development by Sensorion SAS.

He received his undergraduate degree from the University of Bradford and a doctorate degree from Swansea University.


Posities en verantwoordelijkheden van Graham K. Dixon 
NaamTitel Van
Mithra Pharmaceuticals SA
(Farmaceutische producten)
CSO, Head-Research & Development -
Alligator Bioscience AB (publ)
(Biotechnologie & Medisch Onderzoek)
Independent Director 2019
HepaRegeniX GmbH Chairman -
Zaluvida Holdings Pte Ltd. Head-Research & Development -
InteRNA Technologies BV Director -


Graham K. DixonPersoonlijk netwerk 
Meest gelezen nieuws 
22/09WILLIAM ACKMAN : Ackman's Pershing Square fonds stijgt bij beursdebuut Universal
MR
24/09CATHIE WOOD : Chinese maatregelen tegen bitcoin opnieuw een klap voor Cathie Woods ARK ETF
MR
15/09BRAD SMITH : Microsoft kondigt inkoop van eigen aandelen aan tot $60 mrd, verhoogt dividend
MR
13/09MARTIN SORRELL : Sorrell's S4 Capital verhoogt winstverwachting tot 40%
MR
14/09STEPHEN SCHERR : Goldman Sachs benoemt Coleman als nieuwe CFO, ter vervanging van Scherr
MR
15/09ILHAM KADRI : Activist Bluebell Capital wil ontslag CEO Solvay
AM
Meer nieuws


© 2021 People and Ownership :   
Graham K. Dixon Verbindingen